At present, the standard chemotherapeutic drugs for NSCLC including first line cisplatin and second line highly selective EGFR-directed tyrosine kinase inhibitors such as gefitinib, erlotinib, and afatinib have been suffering from drug resistance [8, 16]. Here, EGFR is linked to non-small cell lung carcinoma.